<b>Cardioprotective Effects of Coenzyme Q10 Supplementation on Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention</b>

Background: We assessed the potential efficacy of Coenzyme Q10 (CoQ10) in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI). Methods: Seventy STEMI who presented ≤12 hours after onset symptoms and were scheduled for PPCI randomly assigned to standard treatments plus CoQ10 or placebo. In group, CoQ10, as an oral capsule at a dose 400 mg, was loaded immediately before continued 200 mg twice daily 28 days. The control group received matching placebo, similarly. study endpoints proportion complete reperfusion, defined thrombolysis (TIMI) flow blush grade (MBG) 3 end PPCI, resolution (≥70%) 60 minutes plasma levels creatine kinase band isoenzyme (CK-MB) troponin I (TnI) 12, 24, 48, 72 left ventricular ejection fraction (LVEF) day 28. Results: groups comparable regarding baseline clinical procedural characteristics. TIMI 3, MBG ST completion similar between groups. Whereas all-time points (12, hours), CK-MB TnI significantly lower than group. Further, 28, CoQ10-treated exhibited better LVEF placebo-treated patients, less 50% Conclusion: Our provided evidence that supplementation might reduce ischemia-reperfusion injury help preserve function. However, further studies are required validate these results.